A Phase 2 interventional study of T-DM1 in Breast Cancer, sponsored by Dana-Farber Cancer Institute. Active, not recruiting at 14 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.
Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms — 11 open to participants now, 16 under way, 2 of them phase 3. Ado-Trastuzumab Emtansine · Breast Neoplasms.
Among the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, this one is the 26th largest by enrollment, is one of 2 that started in 2018, is one of 26 in phase 2, reaches primary completion later than 2 of the 15 other live ones, and was the 41st registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →11 of the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:
University of Chicago · Sites in Nigeria
Ages 18+ · Women only
UNICANCER · Sites in France
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–70 · Women only
University of Virginia · Sites in United States
Ages 18+
By country, each count listing its studies:
Ado-Trastuzumab Emtansine: first FDA approval 2013 (KADCYLA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, Ado-Trastuzumab Emtansine is the treatment under test here. Read study by study →
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 32 · Phase 3 12 · Phase 4 1
First in 2006; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 103 across the 56 interventional studies. Of the 36 that completed or were terminated, 24 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 56 have an industry lead sponsor. The 10 most frequent:
Dana-Farber Cancer Institute is the lead sponsor of 836 studies on the registry; 121 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.
142 studies in Breast Neoplasms by Dana-Farber Cancer Institute: 15 open now, 43 under way, none of them phase 3. Of 95 finished, 45 (47%) have results posted.
Among the 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute, this one is the 35th largest by enrollment of the 132 interventional ones that give a count, is one of 10 that started in 2018, is one of 56 in phase 2, reaches primary completion later than 14 of the 42 other live ones, and was the 88th registered.
Dana-Farber Cancer Institute’s Breast Neoplasms studies by the year they started, since 1998.
3 of the studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06481956Zheng YabingT-DM1 Combined With CDK4/6 Inhibitor Ribociclib | 2027-01-10 |
| NCT04733118MedSIRChemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer | 2027-03 |
| NCT07825753Fudan UniversityProtein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, from their registry updates:
Among Dana-Farber Cancer Institute’s 142 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This research study is studying an investigational drug as a possible treatment for breast cancer that is positive for the protein Human Epidermal Growth Factor Receptor 2, also known as HER2-positive breast cancer.
The drug involved in this study is:
-ado-trastuzumab emtansine (T-DM1)
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied and research doctors are trying to find out more about it-such as the safest dose to use and the side effects it may cause.
The purpose of this research study is to examine the long-term benefits of T-DM1 with regard to breast cancer and take a closer look at the side effects experienced by participants receiving T-DM1.
The FDA (the U.S. Food and Drug Administration) has not approved T-DM1 for use in patients with stage I, II, or III breast cancer, but it has been approved for use in advanced, previously treated, HER2-positive breast cancer.
T-DM1 is an antibody-drug conjugate; it is made up of an antibody (trastuzumab) linked to a cytotoxic drug, DM1 (chemotherapy). T-DM1 functions as a targeted cancer therapy because it targets HER2-positive breast cancer cells directly, limiting exposure of the rest of the body to chemotherapy. More specifically, the trastuzumab in T-DM1 first binds to the HER2 protein on the surface of the breast cancer cells and the DM1 then enters the cells and can cause them to die, preventing tumor growth
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
NOTE: Management of axillary lymph nodes is up to the treating provider; however, all surgical margins should be clear of invasive cancer or DCIS (i.e., no tumor on ink). The local pathologist must document negative margins of resection in the pathology report. If all other margins are clear, a positive posterior (deep) margin is permitted, provided the surgeon documents that the excision was performed down to the pectoral fascia and all tumor has been removed. Likewise, if all other margins are clear, a positive anterior (superficial; abutting skin) margin is permitted provided the surgeon documents that all tumor has been removed.
-≤90 days from the patient's most recent breast surgery for this breast cancer. Note: In cases where registration will occur >90 days from surgery but within an acceptable time frame, patient may be eligible for enrollment with approval from the PI, Rachel Freedman MD, MPH.
The following laboratory values obtained ≤14 days prior to registration:
Exclusion Criteria:
NOTE: A hepatitis panel is required of all participants as part of screening. Patients with positive Hepatitis B or C serologies indicating active infection without known active disease must meet the eligibility requirements for , AST, total , , PTT, and alkaline phosphatase on at least two consecutive occasions, separated by at least 1 week. Patients with laboratory evidence of vaccination to Hepatitis B (e.g., positive antibodies) are eligible.
Significant, active cardiopulmonary dysfunction (i.e. uncontrolled heart issues)as indicated by or echocardiogram performed ≤60 days prior to registration and/or by presence of any of the following:
Any chemotherapy for this breast cancer.
->90 days of tamoxifen therapy, or other hormonal therapy, for adjuvant therapy for this malignancy
History of exposure at any time to the following cumulative doses of anthracyclines:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
T-DM1 will be administered every 3 weeks intravenously, with 21 consecutive days defined as a treatment.
Drug: T-DM1
T-DM1 is an antibody-drug conjugate; it is made up of an antibody (trastuzumab) linked to a cytotoxic drug, DM1 (chemotherapy). T-DM1 functions as a targeted cancer therapy because it targets HER2-positive breast cancer cells directly, limiting exposure of the rest of the body to chemotherapy.
Also known as: Kadcyla
Invasive Disease-free Survival Rate (IDFS)
IDFS is defined as the time from the first T-DM1 dose to ipsilateral invasive breast cancer recurrence, regional invasive breast cancer recurrence, distant recurrence, death due to any cause, contralateral invasive breast cancer, or a second non-breast primary cancer, whichever occurs first. Patients without one of these events at the time of data analysis will be censored at the date last known to be alive and event-free. Survival probabilities (reported as percentages) are estimated from Kaplan Meier methods.
Time frame: 5 years
Invasive Breast Cancer-free Survival (IBCFS)
IBCFS is defined as the time from the first T-DM1 dose to ipsilateral invasive breast cancer recurrence, regional invasive breast cancer recurrence, distant recurrence, death due to any cause, or contralateral invasive breast cancer, whichever occurs first. Patients who experience a second non-breast new primary outcome will be censored at their new primary diagnosis date. Patients without any of these events at the time of data analysis will be censored at the date last known to be alive and event-free. Survival probabilities (reported as percentages) are estimated from Kaplan Meier methods.
Time frame: 5 years
Recurrence-free Interval (RFI)
RFI is defined as the time from the first T-DM1 dose to ipsilateral invasive breast cancer recurrence, regional invasive breast cancer recurrence, or distant recurrence. Patients who experience other IDFS events, such as contralateral invasive breast cancer, a second non-breast primary cancer, or death due to any cause, will be censored at the time of these events. Patients without any of these events at the time of data analysis will be censored at the date last known to be alive and event-free. Survival probabilities (reported as percentages) are estimated from Kaplan Meier methods. Note: The protocol labels this outcome as recurrence-free survival (RFS). However, the definition provided in the protocol, where the recurrences are considered events but deaths are not considered events, matches the definition of recurrence-free interval (RFI) provided in the STEEP version 2.0 paper (Tolaney et al., 2021).
Time frame: 5 years
Overall Survival (OS)
OS defined as the time from the first T-DM1 dose to death attributable to any cause (i.e. death from breast cancer, non-breast cancer cause, or from unknown cause). Subjects alive at the time of data analysis (including those lost to follow-up) will be censored at the last known alive date. Survival probabilities (reported as percentages) estimated from Kaplan Meier methods.
Time frame: 5 years
Site of First Recurrence
The site of the first IDFS event for patients receiving T-DM1, which will be tabulated as frequencies and relative frequencies. IDFS events include ipsilateral invasive breast cancer recurrence, regional invasive breast cancer recurrence, distant recurrence, death due to any cause, contralateral invasive breast cancer, or a second non-breast primary cancer.
Time frame: 5 years
Incidence Rate of All Toxicities (Safety)
Among all patients who received at least one dose of T-DM1 treatment, summarize the maximum treatment-related adverse event reported per subject. Adverse events (AEs) are graded utilizing CTCAE v4.0; AEs of grade 2 to 5 are systematically reported, while grade 1 AEs are not systematically reported, so subjects with no reported AEs (grade 0) and subjects with a maximum grade 1 AE are combined into a single category. AEs are considered treatment-related if they start at or after the first dose of T-DM1 and are determined to be definitely, possibly, or probably related to T-DM1 treatment.
Time frame: 2 years
Incidence Rate of Cardiac-Related Adverse Events: Left Ventricular Systolic Dysfunction
Incidence of symptomatic left ventricular systolic dysfunction in patients receiving T-DM1, recorded as frequencies and percentages.
Time frame: 2 years
Incidence Rate of Cardiac-Related Adverse Events: Cardiac Death
Incidence of deaths due to a cardiac event in patients receiving T-DM1, recorded as frequencies and percentages.
Time frame: 2 years
Incidence Rate of Cardiac-Related Adverse Events: Decreased Ejection Fraction
Incidence of a decrease in ejection fraction by at least 10 percentage points below baseline (measured by an absolute difference) or an ejection fraction below 50%.
Time frame: 2 years
| Milestone | T-DM1 |
|---|---|
| Started | 111 |
| Completed | 111 |
| Not completed | 0 |
IDFS is defined as the time from the first T-DM1 dose to ipsilateral invasive breast cancer recurrence, regional invasive breast cancer recurrence, distant recurrence, death due to any cause, contralateral invasive breast cancer, or a second non-breast primary cancer, whichever occurs first. Patients without one of these events at the time of data analysis will be censored at the date last known to be alive and event-free. Survival probabilities (reported as percentages) are estimated from Kaplan Meier methods.
| Survival percent probability | T-DM1 |
|---|---|
| Survival percent probability at 5 years | 84.2 (77.1 to 92.0) |
| Survival percent probability at 3 years | 91.2 (85.9 to 96.9) |
IBCFS is defined as the time from the first T-DM1 dose to ipsilateral invasive breast cancer recurrence, regional invasive breast cancer recurrence, distant recurrence, death due to any cause, or contralateral invasive breast cancer, whichever occurs first. Patients who experience a second non-breast new primary outcome will be censored at their new primary diagnosis date. Patients without any of these events at the time of data analysis will be censored at the date last known to be alive and event-free. Survival probabilities (reported as percentages) are estimated from Kaplan Meier methods.
| Survival percent probability | T-DM1 |
|---|---|
| Survival percent probability at 5 years | 92.0 (86.9 to 97.5) |
| Survival percent probability at 3 years | 94.1 (89.7 to 98.8) |
RFI is defined as the time from the first T-DM1 dose to ipsilateral invasive breast cancer recurrence, regional invasive breast cancer recurrence, or distant recurrence. Patients who experience other IDFS events, such as contralateral invasive breast cancer, a second non-breast primary cancer, or death due to any cause, will be censored at the time of these events. Patients without any of these events at the time of data analysis will be censored at the date last known to be alive and event-free. Survival probabilities (reported as percentages) are estimated from Kaplan Meier methods. Note: The protocol labels this outcome as recurrence-free survival (RFS). However, the definition provided in the protocol, where the recurrences are considered events but deaths are not considered events, matches the definition of recurrence-free interval (RFI) provided in the STEEP version 2.0 paper (Tolaney et al., 2021).
| Survival percent probability | T-DM1 |
|---|---|
| Survival percent probability at 5 years | 94.9 (90.6 to 99.4) |
| Survival percent probability at 3 years | 95.9 (92.1 to 99.9) |
OS defined as the time from the first T-DM1 dose to death attributable to any cause (i.e. death from breast cancer, non-breast cancer cause, or from unknown cause). Subjects alive at the time of data analysis (including those lost to follow-up) will be censored at the last known alive date. Survival probabilities (reported as percentages) estimated from Kaplan Meier methods.
| Survival percent probability | T-DM1 |
|---|---|
| Survival percent probability at 5 years | 93.3 (88.1 to 98.9) |
| Survival percent probability at 3 years | 96.1 (92.4 to 99.9) |
The site of the first IDFS event for patients receiving T-DM1, which will be tabulated as frequencies and relative frequencies. IDFS events include ipsilateral invasive breast cancer recurrence, regional invasive breast cancer recurrence, distant recurrence, death due to any cause, contralateral invasive breast cancer, or a second non-breast primary cancer.
| Participants | T-DM1 |
|---|---|
| Ipsilateral invasive breast cancer | 1 |
| Regional invasive breast cancer | 0 |
| Contralateral invasive breast cancer | 3 |
| Distant recurrence | 3 |
| Non-breast new primary invasive cancer | 7 |
| Death due to breast cancer | 2 |
| Death due to other non-breast cancer reason | 1 |
| Alive and event-free at last follow-up | 94 |
Among all patients who received at least one dose of T-DM1 treatment, summarize the maximum treatment-related adverse event reported per subject. Adverse events (AEs) are graded utilizing CTCAE v4.0; AEs of grade 2 to 5 are systematically reported, while grade 1 AEs are not systematically reported, so subjects with no reported AEs (grade 0) and subjects with a maximum grade 1 AE are combined into a single category. AEs are considered treatment-related if they start at or after the first dose of T-DM1 and are determined to be definitely, possibly, or probably related to T-DM1 treatment.
| Participants | T-DM1 |
|---|---|
| Grade 0 (no toxicity) or grade 1 (mild) | 20 |
| Grade 2 (moderate) | 59 |
| Grade 3 (severe) | 31 |
| Grade 4 (life-threatening) | 1 |
| Grade 5 (death related to toxicity) | 0 |
Incidence of symptomatic left ventricular systolic dysfunction in patients receiving T-DM1, recorded as frequencies and percentages.
| Participants | T-DM1 |
|---|---|
| Symptom of left ventricular systolic dysfunction observed | 4 |
| No symptom of left ventricular systolic dysfunction observed | 107 |
Incidence of deaths due to a cardiac event in patients receiving T-DM1, recorded as frequencies and percentages.
| Participants | T-DM1 |
|---|---|
| Cardiac death | 0 |
| Death not observed in follow-up or death due to non-cardiac cause | 111 |
Incidence of a decrease in ejection fraction by at least 10 percentage points below baseline (measured by an absolute difference) or an ejection fraction below 50%.
| Participants | T-DM1 |
|---|---|
| Decrease in ejection fraction by at least 10 percentage points below baseline | 11 |
| Ejection fraction decreased below 50% | 1 |
| No ejection fraction cardiac toxicity observed | 99 |
Collected over Adverse Events were assessed up to 2 years. Deaths were assessed up to 5 years.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T-DM1 | 6/111 (5.4%) | 17/111 (15.3%) | 111/111 (100%) |
| Event | T-DM1 |
|---|---|
| FeverGeneral disorders | 2/111 |
| Lung infectionInfections and infestations | 2/111 |
| FallInjury, poisoning and procedural complications | 2/111 |
| AnemiaBlood and lymphatic system disorders | 1/111 |
| ColitisGastrointestinal disorders | 1/111 |
| Gastric hemorrhageGastrointestinal disorders | 1/111 |
| Gastrointestinal disorders - Other, specifyGastrointestinal disorders | 1/111 |
| FatigueGeneral disorders | 1/111 |
| Hepatobiliary disorders - Other, specifyHepatobiliary disorders | 1/111 |
| Bladder infectionInfections and infestations | 1/111 |
| Event | T-DM1 |
|---|---|
| FatigueGeneral disorders | 92/111 |
| Aspartate aminotransferase increasedInvestigations | 82/111 |
| NauseaGastrointestinal disorders | 65/111 |
| Peripheral sensory neuropathyNervous system disorders | 64/111 |
| Dry mouthGastrointestinal disorders | 62/111 |
| Alanine aminotransferase increasedInvestigations | 56/111 |
| AnorexiaMetabolism and nutrition disorders | 53/111 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 53/111 |
| Platelet count decreasedInvestigations | 52/111 |
| MyalgiaMusculoskeletal and connective tissue disorders | 50/111 |
Participants who received at least one dose of T-DM1 treatment
| Age, Continuous(Years) | T-DM1 |
|---|---|
| Median | 71 (60 to 88) |
| Age, Customized(Participants) | T-DM1 |
|---|---|
| Age at enrollment — 60 to 65 years | 33 |
| Age at enrollment — 66 to 70 years | 22 |
| Age at enrollment — 71 to 75 years | 25 |
| Age at enrollment — 76 to 80 years | 18 |
| Age at enrollment — Over 80 years | 13 |
| Sex: Female, Male(Participants) | T-DM1 |
|---|---|
| Female | 102 |
| Male | 1 |
| Ethnicity (NIH/OMB)(Participants) | T-DM1 |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 83 |
| Unknown or Not Reported | 26 |
| Race/Ethnicity, Customized(Participants) | T-DM1 |
|---|---|
| Race — Asian | 3 |
| Race — Black or African American | 5 |
| Race — White | 79 |
| Race — Other or Unknown | 24 |
| ECOG Performance Status(Participants) | T-DM1 |
|---|---|
| 0 (fFully active; able to carry out all pre-disease activities without restriction) | 88 |
| 1 (Restricted in physically strenuous activity, but ambulatory and able to carry out light work) | 21 |
| 2 (Ambulatory and capable of all self-care, but unable to carry out any work activities) | 2 |
| Clinical stage at primary breast cancer diagnosis(Participants) | T-DM1 |
|---|---|
| Stage I | 77 |
| Stage II | 29 |
| Stage III | 5 |
| Tumor size (cm) - largest pathologic focus of primary invasive tumor(Participants) | T-DM1 |
|---|---|
| <1 cm | 22 |
| 1-2 cm | 56 |
| 2-5 cm | 29 |
| >5 cm | 4 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2018 to primary completion in Mar 2025, 78 months.
Results were first posted in Apr 2026, 1 year 1 month after primary completion.
Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's 78 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ado-Trastuzumab Emtansine
Dana-Farber Cancer Institute →